- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 213/30 - Oxygen atoms
Patent holdings for IPC class C07D 213/30
Total number of patents in this class: 647
10-year publication summary
|
49
|
64
|
57
|
44
|
49
|
44
|
39
|
37
|
32
|
4
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 5080 |
11 |
| Abbvie Inc. | 1808 |
11 |
| JNC Corporation | 1527 |
11 |
| Unigen, Inc. | 118 |
11 |
| JNC Petrochemical Corporation | 425 |
10 |
| Sumitomo Chemical Company, Limited | 8808 |
9 |
| Global Blood Therapeutics, Inc. | 180 |
8 |
| Purdue Pharma L.P. | 519 |
8 |
| Mycovia Pharmaceuticals, Inc. | 40 |
8 |
| Novartis AG | 11238 |
7 |
| F. Hoffmann-La Roche AG | 7958 |
7 |
| AstraZeneca AB | 3042 |
7 |
| The Regents of the University of California | 18943 |
6 |
| Chiesi Farmaceutici S.p.A. | 940 |
6 |
| BASF SE | 19740 |
5 |
| Allergan, Inc. | 2600 |
5 |
| Takeda Pharmaceutical Company Limited | 2961 |
5 |
| Galderma Research & Development | 440 |
5 |
| Mcmaster University | 746 |
5 |
| vTv Therapeutics LLC | 159 |
5 |
| Other owners | 497 |